A Study of RG-012 in Subjects With Alport Syndrome
Status:
Completed
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and
pharmacokinetics of RG-012 administered to subjects with Alport syndrome.